🎉🙌 Another new study w/ MAST investigators 🔬👇 Narrow-band UVA exposure is effective against all SARS-CoV-2 variants tested, suggesting that internal UVA therapy can potentially serve as a stand-alone or adjunct therapy for COVID-19 Cedars-Sinai Academic Medicine doi.org/10.1016/j.pdpd…

Our newest study in Annals of Int Med evaluating the nationwide trend in GLP-1RA prescription patterns found: 👉Significant 📈 in use since 2011, esp post-2020 👉Proportion of new users w/ T2D ⬇️ while those w/ obesity without T2D ⬆️ 👉Semaglutide (Ozempic, Wegovy) made up the

Another ICYMI #DDW2024 edition❗️ Our abstract found that severity of self-reported bloating correlates w/ excessive growth of coliforms, meeting the definition of #SIBO in the duodenum Digestive Disease Week Cedars-Sinai Academic Medicine

Take a look at this insightful SELF health article featuring MAST investigator/GI expert Mark Pimentel MD‼️ He warns readers about using drugs to treat individual GI symptoms, noting it may lead to a "flip-flopping effect" between bowel issues self.com/story/constipa…

In the Cedars-Sinai Academic Medicine Newsroom! 🗞️ Our 2 latest papers were featured recently. Be sure to check out these excellent summaries of MAST research 😀 ➡️ cedars-sinai.org/newsroom/study… ➡️ cedars-sinai.org/newsroom/new-c…

Continuous glucose monitors help patients with T1D & T2D stabilize their blood sugar levels but can also help those without diabetes optimize their health! Cedars-Sinai blog interviewed MAST endocrinologist Ruchi Mathur MD for this insightful article! 👇 cedars-sinai.org/blog/continuou…

Latest MAST paper just published in Scientific Reports!! In an animal model, the optimal Rifaximin+NAC combo: 1) normalized stool consistency 2) ⬇️ small bowel bacterial levels 3) ⬇️ E. coli & Desulfovibrio spp. 4) normalized cytokine levels better than Rifaximin alone, suggesting

This SAVEUR article, in which MAST's Mark Pimentel MD is quoted, explains how unfamiliar foods, disrupted routines & local bacteria can cause travelers GI issues like bloating or diarrhea "The path of physiology is related to the equator." Read more: saveur.com/culture/travel…

Celebrating Healthcare Heroes Week at Cedars-Sinai! Huge thanks to all staff members for all that you do and special shoutout to our incredible team of MASTers for for driving innovation in gut #microbiome research. Together, we're making a difference 😊

This recent BBC Health Check podcast includes MAST's Ali Rezaie MD MSc interview where he discusses why it's crucial to understand GLP-1 prescription trends as they become more widely used BBC Health News Cedars-Sinai Academic Medicine Listen here: bbc.co.uk/sounds/play/w3… Time stamp: 12:15 – 18:05

🚨🚨 New systematic review/meta-analysis from MAST investigators summarizing GI symptoms associated with IMO reveals that patients with #IMO show higher rates and severity of constipation, but lower rates and severity of diarrhea Cedars-Sinai Academic Medicine doi.org/10.1016/j.cgh.…

On #NationalPatientAdvocacyDay today, we celebrate the importance of patient voices in driving healthcare innovation. MAST is committed to advancing research to better understand gut #microbiome-related diseases, ensuring patients get the care they deserve! Cedars-Sinai

It's official - MAST investigators are heading to #ACG2024 conference in October!! Looking forward to sharing our latest research 😊 ACG Cedars-Sinai Academic Medicine

Have you read it yet? This New York Post health article on the link between red & processed meats and #T2D quotes MAST’s endocrinologist Ruchi Mathur MD. She explains the pros and cons of red meat on human health nypost.com/2024/08/20/lif…

Exciting developments!! The findings in our paper pave the way to establish validated disease-specific patient reported outcomes. Future studies that include correlative archaeome assessments are key to deepening our understanding of #IMO Thanks for sharing 😊

Poor solubility of rifaximin may limit its efficacy against microbes in the mucus layer. .Mark Pimentel MD et al. found low-dose rifaximin combined with N-acetylcysteine is superior to rifaximin alone in a rat model of IBS-D: nature.com/articles/s4159…

September is #PCOSAwarenessMonth! This year's theme is "Voices of Strength, Agents of Change", calling stakeholders to support patient-centered research. That's where MAST comes in! Throwback to our posters at #ENDO2024 on #PCOS & the gut #microbiome Cedars-Sinai Academic Medicine

A special day with patient 1000 in the REIMAGINE study. A massive effort to study the small intestinal #microbiome and new associations between single bacteria and human disease. Thanks to those who support this research! You will see great things in the coming months.

Today we’re thrilled to announce that our REIMAGINE study has reached a MAJOR milestone - 1,000 patients enrolled! 🎉 This study has been groundbreaking in advancing our understanding of the human small intestinal #microbiome & we can’t wait to see what new discoveries lie ahead